The Longevity Economy: Will the Rich Buy More Years of Life?
Money is flowing into the anti-aging industry and into companies that promise to slow aging and add healthy years.
That sounds like good news, but it raises a question of fairness. If only wealthy people can afford these treatments, a new layer of health inequality could form on top of the one we already have.
In this article we will explain how the longevity economy works and who is paying for it. We will also look at what it could mean for inequality in life expectancy.
The Rise of the Longevity Economy
The longevity economy includes every product and service built to help people live longer and stay healthy as they age, such as:
- Medicines that target aging cells
- Genetic and biological age tests
- Wearable devices
- Supplements
- Private health clinics
The anti-aging industry is one part of this market. It focuses on slowing or even reversing the biological process of aging. Some products are simple, like skin creams and vitamins, while others are advanced, like new drugs still in research.
Three things drive the growth:
- Aging populations → More people want good health in later life.
- Fast science → Tools for studying genes and cells keep improving.
- Investor interest → Many analysts place the anti-aging industry in the hundreds of billions of dollars worldwide.
Why Billionaires Are Investing in Longer Lives
The longevity economy has attracted some of the world’s richest people. Here are some well-known examples:
- Altos Labs studies cell rejuvenation and has been reported to have backing from Jeff Bezos and Yuri Milner.
- Calico, founded by Google, researches the biology of aging.
- Retro Biosciences is backed by Sam Altman.
- Bryan Johnson spends millions each year on a strict health program and shares the results publicly.
1. Now Wealth Can Buy More Time!
A billionaire can buy houses, planes, and companies, but time is the one thing money cannot buy. Longevity research gives them a chance to change that.
2. Aging Research Is a Long-term Investment
Drugs that slow aging or treat age-related diseases could sell to millions of people. That makes this field a real business opportunity. Investors hope that early support will bring big returns later.
3. The Market Is Extremely Huge
The world’s population is getting older. A drug that slows aging, or one that treats age-related diseases, could sell to hundreds of millions of people. Investors see this as one of the biggest markets in medicine.
4. Billionaires Can Afford Risky Bets
Aging research takes many years and often fails. Governments and small companies usually cannot wait that long. Billionaires can, because they do not need a quick return.
Their funding can speed up science, and that may help everyone in the end. Still, new treatments usually start out expensive. The early benefits of the anti-aging industry therefore tend to go to people who can pay. The attention from billionaires also shows that the longevity economy is now taken seriously.
When Living Longer Becomes a Luxury
Health inequality has always existed. Richer people usually eat better and live in safer places. They also tend to work in less risky jobs and see doctors more easily. Longevity technology adds another layer. Private clinics already offer full-body scans and personalized testing. Some also sell hormone therapies. Together these can cost thousands of dollars a year.
This is where health inequality could grow wider. Basic care is still out of reach for many people. If advanced treatments appear first for the rich, the longevity economy could turn extra years into a product that is sold instead of a right that is shared. Many anti-aging treatments are also unproven. Wealthy buyers can afford to experiment, while many other people cannot afford even proven care.
The Wealth Gap in Life Expectancy
A well-known 2016 study in JAMA looked at US tax and death records. It found that the richest 1% of men lived about 14.6 years longer than the poorest 1%. For women, the gap was about 10.1 years. This is a clear example of inequality in life expectancy.
Inequality in life expectancy exists inside other rich countries too. According to ONS, men born in the most deprived areas of England can expect to live about 73.2 years. Men in the least deprived areas can expect about 83.6 years. That is a gap of more than 10 years, and for women it is about 8 years.
The causes are well known. Income and education matter, and so do clean water and good nutrition. Safe housing and access to doctors play a part too. Longevity technology could make the gap larger, because it gives a new advantage to people who are already ahead.
Will Anti-Aging Become a Privilege in the Future?
Many medical advances start out expensive and become cheaper over time. Anti-aging treatments could follow the same pattern, and the access can be slowed by:
- High prices set by companies protected by patents
- Health systems that cannot afford new treatments
- Treatments that need advanced testing and specialist doctors
- Little research on diseases that mainly affect poor communities
The anti-aging industry earns money from paying customers, so it has a natural reason to serve them first. If prices stay high, the anti-aging industry will mostly serve wealthy customers, and health inequality will widen. Anti-aging treatments would then remain a privilege, and access would depend on income and country of residence.
Who Gets to Live Longer in the Future?
No one knows exactly how far longevity science will go. Some researchers expect modest gains in healthy years, while others expect bigger breakthroughs. Either way, how these tools are shared will matter as much as the science.
Practical steps that governments and health systems can take:
- Fund research publicly, so results stay open to all.
- Set fair pricing rules and support generic medicines.
- Invest in basic care, nutrition, and clean environments.
- Regulate clinics that sell exclusive and confidential treatments.
Policies like this can reduce health inequality and help ensure that the benefits of longer lives and medical advances are not limited to those who can afford them.
Conclusion
The longevity economy is attracting billionaires and large investments, and the anti-aging industry is expanding fast. The danger is that the benefits arrive faster and better for people who already live longer.
Inequality in life expectancy is already measured in years, and it could grow even wider if access to new health technologies is left to the market alone. Public investment, fair access, and stronger basic healthcare systems can help ensure that longer lives become a shared benefit, not a privilege for the few.
